11 hrs ago
Medivation Receives Hold Rating from Canaccord Genuity
's stock had its "hold" rating reiterated by research analysts at Canaccord Genuity in a report released on Wednesday, Analyst Ratings News reports.
Trending on the Topix Network
Mon Apr 14, 2014
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys
The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months.
Thu Apr 03, 2014
Astellas Pharma US Announces European Regulatory Submission For...
The Phase 3 PREVAIL trial is a randomized, double-blind, placebo-controlled, multi-national trial that enrolled more than 1,700 patients at sites in .
Earnings Releases, Stock Price Movements, Company Milestone,...
Information contained on this page is provided by an independent third-party content provider.
Mon Mar 31, 2014
Medivation Names Rick Bierly Chief Financial Officer
Rick will serve as Medivation's principal financial and accounting officer and will report to David Hung, M.D., president and chief executive officer.
NCCN Receives $2.2 Million in Research Funding From Astellas and...
The National Comprehensive Cancer Network A Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and ... (more)
Thu Mar 27, 2014
Astellas And Medivation Seek New Indication For Xtandi In sNDA To FDA
Astellas Pharma Inc. and Medivation Inc. announced in a press release that they submitted a Supplemental New Drug Application to the Food and Drug Administration .
Mon Mar 24, 2014
Customer Interaction Solutions
Astellas Announces Marketing Approval in Japan for XTANDI...
Astellas Pharma Inc. today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI capsules 40mg for the treatment of patients with castration-resistant prostate cancer in Japan.
Fri Mar 21, 2014
The Motley Fool
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers.
Tue Mar 18, 2014
Astellas and Medivation Submit Supplemental New Drug Application for...
XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy.